BIA-ALCL GC Aesthetics Communication update

We continue to closely monitor BIA-ALCL.

The Australian Therapeutic Good Administration (TGA) has released a public statement of the preliminary outcomes from its review of textured implants on July 11, 2019. The notice proposes certain actions the TGA may take in relation to textured implants used in Australia. GC Aesthetics is surprised about this public statement, given the overall very low occurrence rate of BIA-ALCL compared to other medical conditions. It is important to notice that no final decision has been taken at this stage. GCA, as well as other responsible manufacturers, are transparently communicating with TGA and stand by our robust data and clinically proven safety

GC Aesthetics’ implant safety has been proven through a number of large scale, long term prospective clinical studies in over 1000 patients, including the only two large scale prospective European study of breast implants with 10-year patient follow up. With over 3 million implants sold over the last 10 years across 70 countries GCA’s safety record is quite clear:

  •   The global rate of BIA-ALCL associated with GCA textured implants is <0.0007%
  •   The global rate of BIA-ALCL associated with GCA smooth implants is 0%

GCA is at the forefront of the industry with a prominent and permanent focus on patient safety. We will continue to closely monitor the incidence of BIA- ALCL and participate in collaborative global research. We also remain committed to transparency with our doctors and patients about this and any other safety concerns.

Yours sincerely,

Carlos Reis Pinto CEO

We also think you’ll like…

COVID-19 – Information for our Global Community

COVID-19 – Information for our Global Community

Dear partners, The health and wellbeing of our staff, customers and partners is a priority for all of us at GC Aesthetics. We recognise that this is an exceptional time of uncertainty and rapid change for everyone in our global community. Within GC Aesthetics our...